Gilead (GILD)

Executive Summary

Gilead Sciences is a global biopharmaceutical leader with a strong legacy in virology, particularly HIV and hepatitis, and a growing presence in oncology and inflammation. The company's commercial portfolio includes blockbuster therapies such as Biktarvy, Descovy, and Trodelvy, generating stable revenue streams. Gilead's pipeline is robust, with key late-stage assets like lenacapavir for HIV prevention and domvanalimab for solid tumors. The company has 29 FDA-approved products and a proven track record of innovation, supported by a strong balance sheet with over $150 billion in market capitalization. Recent acquisitions and partnerships have strengthened its oncology pipeline, positioning Gilead for sustained growth beyond its traditional virology franchise. Financially, Gilead maintains a solid cash position and generates consistent free cash flow, enabling continued investment in R&D and strategic M&A. The company faces near-term challenges from patent expirations and generic competition in its HIV portfolio, but its pipeline and new product launches are expected to offset these headwinds. With a focus on transformative therapies for serious diseases, Gilead is well-positioned to deliver long-term value. Key catalysts over the next 12-18 months include regulatory decisions for lenacapavir in PrEP, Phase 3 data for domvanalimab in non-small cell lung cancer, and potential label expansions for Trodelvy in earlier breast cancer settings.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on lenacapavir for HIV pre-exposure prophylaxis (PrEP)80% success
• H2 2026Phase 3 data readout for domvanalimab (anti-TIGIT) in combination with chemotherapy in first-line non-small cell lung cancer60% success
• Q1 2027FDA approval decision for Trodelvy in first-line metastatic triple-negative breast cancer based on ASCENT-03 trial70% success